LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been given an average rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $69.17.

A number of equities analysts have recently weighed in on LIVN shares. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. Finally, Mizuho dropped their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st.

LivaNova Stock Up 1.0 %

LivaNova stock opened at $47.99 on Friday. LivaNova has a twelve month low of $43.15 and a twelve month high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market cap of $2.61 billion, a PE ratio of 114.26 and a beta of 1.00. The firm’s 50 day moving average price is $48.12 and its two-hundred day moving average price is $49.54.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Several hedge funds have recently added to or reduced their stakes in LIVN. Nordea Investment Management AB lifted its holdings in shares of LivaNova by 22.2% during the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after buying an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new position in LivaNova during the 4th quarter valued at $1,954,000. KBC Group NV boosted its holdings in LivaNova by 130.5% in the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after purchasing an additional 56,580 shares during the period. Allspring Global Investments Holdings LLC grew its position in LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after purchasing an additional 25,277 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its holdings in shares of LivaNova by 38.3% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares during the period. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.